Ask AI
ProCE Banner Activity

Call To Action: Individualizing Treatment Plans in Resectable Early-Stage NSCLC

Clinical Thought

This Call to Action commentary highlights persistent practice challenges and barriers identified by healthcare professionals caring for patients with resectable early-stage NSCLC, related to optimizing the timing and cross-disciplinary coordination of molecular testing and implementing immunotherapy regimens into the care of these patients. The challenges identified in this commentary will be a focus of our upcoming educational program on this topic.

Released: June 04, 2026

Share

Provided by

 Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for medical oncologists, surgical oncologists, surgeons, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals involved in the multidisciplinary care of patients with resectable early-stage NSCLC in community and academic practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with resectable early-stage NSCLC who are eligible for immunotherapy through evidence-based molecular testing

  • Design a personalized multimodal treatment plan for immunotherapy-eligible patients with resectable early-stage NSCLC based on the latest data and expert recommendations

  • Counsel all eligible patients on the risk–benefit profile, goals, and administration options for neo/adjuvant immunotherapy-based treatment using evidence-based resources 

  • Manage immune-related adverse events concordant with the latest guidelines to optimize the quality of life and clinical outcomes for each patient with early-stage resectable NSCLC

Disclosure

Primary Author

Patrick Forde, MD, PhD: researcher: AstraZeneca, BioNTech, Bristol Myers Squibb, Regeneron, Summit; consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Flame, Fosun, F-Star, G1, Genentech, Iteos, Janssen, Novartis, Regeneron, Sanofi.

Karen Reckamp, MD, FASCO: consultant/advisor/speaker: AstraZeneca, Genentech, GSK, Immunity Bio, Johnson & Johnson, Lilly, Novartis, Nuvation, Pfizer; researcher (paid to institution): Avenzo, BioNTech, Johnson & Johnson.